Transparency Market Research Peptide Therapeutics Market is growing at a CAGR of 8.7% from 2013 to 2019. By Transparency Market Research.
Single User License:
USD 4595 Multi User License:
USD 7595 Corporate User License:
USD 10595
Published Date 13-March-2013
128 Page Report
Request Sample
Buy Now
Press Release
Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Peptide Therapeutics Market
REPORT DESCRIPTION
Peptide Therapeutics Market was valued at USD 14.1 billion in 2013 and is estimated to reach a market worth USD 25.4 billion in 2019 at a CAGR of 8.7% from 2013 to 2019.
Browse the full report at http://www.transparencymarketresearch.com/peptidetherapeutics-market.html
The growth of the market is driven by factors such as rising incidences of cardiovascular diseases, metabolic diseases and technological enhancement in peptide synthesis. The Asian region offers future growth prospects to the peptide industry owing to vast unmet medical needs and rising disposable income of patients.
Amongst the application market, the cancer peptide segment accounted for the largest share of approximately 21% and is expected to grow at a healthy CAGR during the forecast period. The neuropeptides application segment is anticipated to grow at a CAGR of 9.4% from 2012 to 2018 due to the rise in number of neurological disorders such as Alzheimer's and Parkinson's disease. The parenteral route of administration of peptides accounted for the largest share of around 86% in year 2011, in terms of routes of administration; however other routes of administration like oral, pulmonary, nasal and intradermal are also being tested and are estimated to experience healthy growth rate during the forecast period.
Technological enhancement with introduction of hybrid technology along with solid phase peptide syntheses (SPPS) is expected to enhance the growth of peptide therapeutics. The hybrid technology segment which provides the best of both solid and liquid syntheses is now being adopted by major players and hence this market is expected to see the highest growth of 12.1% from 2012 to 2018.
Transparency Market Research
2
Peptide Therapeutics Market
The North American peptide therapeutics market held majority of the market share of approximately 40% in 2011 owing to its developed economy. However, due to rise in cost containment and budgetary cuts in North America, emerging countries such as India, China and other Latin American countries is expected to see a healthy growth in the study period. Some of the key market players are Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsen and others. The contract manufacturing organization (CMO) industry includes major players such as Bachem, Polypeptide Group, Lonza, Peptisyntha and others.
Peptide Therapeutics Market, by Applications Cancer Metabolic Cardiovascular Dermatology Anti-Infection Neurology Gastro Intestinal Renal Respiratory Pain Others Peptide Therapeutics Market, by Route of Administration Parenteral Oral Pulmonary
Transparency Market Research
3
Peptide Therapeutics Market
Mucosal Others Peptide Therapeutics Market, by Types Innovative Generics Peptide Therapeutics Market, by API Peptide In-House CMO (Contract Manufacturing Organization) Peptide Therapeutics by technology Liquid Phase Peptide Synthesis (LPPS) Solid Phase Peptide Synthesis (SPPS) Hybrid Peptide Therapeutics Market, by Geography North America Europe Asia RoW
For Sample Report Visit On: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418
Transparency Market Research
4
Peptide Therapeutics Market
TABLE OF CONTENT
Chapter 1 Introduction 1.1 Report description 1.2 Market segmentation 1.3 Scope of the report 1.4 Research methodology 1.5 Assumptions
Chapter 2 Executive Summary 2.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million) 2.1.1 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million) 2.1.2 Global API peptide therapeutics market, 2011 (USD Million) 2.1.3 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)
Chapter 3 Global Peptide Therapeutics Market Dynamics 3.1 Overview 3.2 Drivers 3.2.1 Increase in cancer patient population to propel the growth of new peptides
Transparency Market Research
5
Peptide Therapeutics Market
3.2.2 Rise in metabolic disorders to escalate the growth of peptides market 3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years 3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011 3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides 3.3 Restraints & challenges 3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers 3.3.2 Lack of regulatory standards hampering the growth of the market 3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers 3.4 Opportunities 3.4.1 Rise in cancer vaccine to drive the future market 3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period 3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth 3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants 3.4.3.2 Major peptide drugs and sales, 2011 (USD Million) 3.5 Porters five forces analysis 3.5.1 Porter’s five forces analysis of global peptide therapeutics market 3.5.2 Bargaining power of suppliers
Transparency Market Research
6
Peptide Therapeutics Market
3.5.3 Bargaining power of buyers 3.5.4 Threat of new entrants 3.5.5 Threat of substitutes 3.5.6 Competitive rivalry 3.6 Market attractiveness analysis 3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography 3.7 Peptide therapeutics - emerging technologies & trends 3.8 Regulatory policies
Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications 4.1 Introduction 4.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million) 4.1.2 Cancer 4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million) 4.1.3 Metabolic 4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
Transparency Market Research
7
Peptide Therapeutics Market
4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million) 4.1.4 Cardiovascular 4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million) 4.1.5 Dermatology 4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million) 4.1.6 Anti-Infection 4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012 4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million) 4.1.7 Neurology 4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million) 4.1.8 Gastro Intestinal 4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million) 4.1.9 Renal 4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
Transparency Market Research
8
Peptide Therapeutics Market
4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million) 4.1.10 Respiratory 4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million) 4.1.11 Pain 4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million) 4.1.12 Others 4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012 4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)
Chapter 5 Global Peptide Therapeutics Market, by Route of Administration 5.1 Introduction 5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million) 5.1.2 Methods of delivery for peptide drugs 5.2 Parenteral Route 5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 5.3 Oral Route
Transparency Market Research
9
Peptide Therapeutics Market
5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 2018 (USD Million) 5.4 Pulmonary Route 5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 5.5 Mucosal Route 5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 5.6 Others (Intradermal & Nasal) 5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million)
Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments 6.1 Introduction 6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million) 6.2 Peptide Therapeutics – Innovative market 6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million) 6.3 Peptide Therapeutics – Generic market 6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
Transparency Market Research
10
Peptide Therapeutics Market
7.1 Introduction 7.2 API peptide therapeutics – In-house market 7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million) 7.3 Contract Manufacturing Organizations (CMO) 7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)
Chapter 8 Peptide Therapeutics Market, By Technology 8.1 Introduction 8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million) 8.2 Solid Phase Peptide Synthesis (SPPS) 8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million) 8.3 Liquid Phase Peptide Synthesis (LPPS) 8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million) 8.4 Hybrid Technology 8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)
Chapter 9 Peptide Therapeutics Market, By Geography
Transparency Market Research
11
Peptide Therapeutics Market
9.1 Introduction 9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018 9.2 North America 9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million) 9.3 Europe 9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million) 9.4 Asia 9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 9.5 Rest of World 9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 10 Market Share Analysis 10.1 Market share by key players 10.2 Market share by key players in peptide drugs market 10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%) 10.3 Market share by key players in CMO segment 10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)
Chapter 11 Recommendations 11.1 Success strategies
Transparency Market Research
12
Peptide Therapeutics Market
11.1.1 Rigorous research and development (R&D) initiatives 11.1.2 Investing in emerging economies 11.1.3 Investing in recent technologies such as HPPS TEchnology 11.1.4 Mergers and acquisitions 11.2 Barriers to be considered 11.2.1 The high cost of peptide synthesis 11.2.2 Weak pipeline peptide drug candidates in phase III
Chapter 12 Company Profiles 12.1 Bachem Holding AG 12.1.1 Company overview 12.1.2 Financial overview 12.1.3 Strategic overview 12.1.3.1 Collaborations 12.1.3.2 Expansion 12.1.3.3 Divestiture 12.1.3.4 Recent developments 12.2 Eli Lilly and Company 12.2.1 Company overview 12.2.2 Financial overview
Transparency Market Research
13
Peptide Therapeutics Market
12.2.3 Strategic overview 12.2.3.1 Agreements 12.2.3.2 Approvals 12.2.4 Recent developments 12.3 Pfizer, Inc. 12.3.1 Company overview 12.3.2 Financial overview 12.3.3 Strategic overview 12.3.3.1 Mergers and acquisitions 12.3.3.2 Divestiture 12.3.3.3 Approvals 12.3.4 Recent developments 12.4 Amgen, Inc. 12.4.1 Company overview 12.4.2 Financial overview 12.4.3 Strategic overview 12.4.3.1 Mergers and acquisitions 12.4.3.2 Licensing 12.4.4 Recent developments 12.5 Takeda Pharmaceutical Company Limited
Transparency Market Research
14
Peptide Therapeutics Market
12.5.1 Company overview 12.5.2 Financial overview 12.5.3 Strategic overview 12.5.3.1 Partnerships and collaborations 12.5.3.2 Mergers and acquisitions 12.5.4 Recent developments 12.6 Teva Pharmaceuticals 12.6.1 Company overview 12.6.2 Financial overview 12.6.3 Strategic overview 12.6.3.1 Mergers and acquisitions 12.6.3.2 Investing in generic and biosimilar segments 12.6.4 Recent developments 12.7 Lonza Inc. 12.7.1 Company overview 12.7.2 Financial overview 12.7.3 Strategic overview 12.7.3.1 Investing in emerging economies 12.7.3.2 Mergers and acquisitions 12.7.4 Recent developments
Transparency Market Research
15
Peptide Therapeutics Market
12.8 Peptisyntha 12.8.1 Company overview 12.8.2 Financial overview 12.8.3 Strategic overview 12.8.3.1 Arranging and participating in trade shows 12.8.3.2 Continuous manufacturing expansion 12.9 Sanofi 12.9.1 Company overview 12.9.2 Financial overview 12.9.3 Strategic overview 12.9.3.1 Acquisitions 12.9.3.2 Divestments 12.9.4 Recent developments 12.10 Ipsen 12.10.1 Company overview 12.10.2 Financial overview 12.10.3 Strategic overview 12.10.3.1 Large investment in research and development 12.10.3.2 Global expansion through partnership 12.10.4 Recent developments
Transparency Market Research
16
Peptide Therapeutics Market
12.11 PolyPeptide Group. 12.11.1 Company overview 12.11.2 Strategic overview 12.11.2.1 Focus on product portfolio extension and quality product development 12.11.2.2 Global expansion through merger and acquisition 12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS) 12.12.1 Company overview 12.12.2 Amylin Pharmaceuticals LLC 12.12.3 Financial overview 12.12.4 Strategic overview (Amylin Pharmaceuticals LLC) 12.12.4.1 Entering into strategic collaborations 12.12.4.2 Corporate social responsibility 12.12.4.3 Rigorous R&D initiatives 12.12.5 Recent developments 12.13 AstraZeneca PLC 12.13.1 Company overview 12.13.2 Financial overview 12.13.3 Strategic overview 12.13.3.1 Rigorous R&D initiatives 12.13.3.2 Investing in emerging economies
Transparency Market Research
17
Peptide Therapeutics Market
12.13.4 Recent developments 12.14 Roche 12.14.1 Company overview 12.14.2 Financial overview 12.14.3 Strategic overview 12.14.3.1 Research and development initiatives 12.14.3.2 Focus on personalized healthcare 12.14.3.3 Focus on new and emerging markets 12.14.3.4 Funding awareness programs 12.14.4 Recent developments 12.15 GlaxoSmithKline (GSK) 12.15.1 Company overview 12.15.2 Financial overview 12.15.3 Strategic overview 12.15.3.1 Research and development initiatives 12.15.3.2 Direct to Consumer Advertising 12.15.3.3 Mergers and acquisitions 12.15.4 Recent developments 12.16 Merck & Co. 12.16.1 Company overview
Transparency Market Research
18
Peptide Therapeutics Market
12.16.2 Financial overview 12.16.3 Strategic overview 12.16.3.1 Corporate social responsibility 12.16.3.2 R&D Initiatives 12.16.3.3 Strategic alliances and out-licensing 12.16.4 Recent developments 12.17 Novartis AG 12.17.1 Company overview 12.17.2 Financial overview 12.17.3 Strategic overview 12.17.3.1 Mergers and acquisitions 12.17.3.2 Memorandum of understanding 12.17.4 Recent developments 12.18 Novo-Nordisk A/S 12.18.1 Company overview 12.18.2 Financial overview 12.18.3 Strategic overview 12.18.3.1 Partnerships and alliances 12.18.4 Agreements 12.18.5 Recent developments
Transparency Market Research
19
Peptide Therapeutics Market
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
20